7/5
03:27 pm
allo
Car T-Cell Therapy Market size is set to grow by USD 3.02 billion from 2024-2028, Growing awareness regarding car T-cell therapy to boost the market growth, Technavio [Yahoo! Finance]
Low
Report
Car T-Cell Therapy Market size is set to grow by USD 3.02 billion from 2024-2028, Growing awareness regarding car T-cell therapy to boost the market growth, Technavio [Yahoo! Finance]
7/1
08:45 am
allo
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Low
Report
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
7/1
08:30 am
allo
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Low
Report
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
6/27
11:27 am
allo
With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns [Yahoo! Finance]
Low
Report
With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns [Yahoo! Finance]
6/27
10:22 am
allo
Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock? [Yahoo! Finance]
Medium
Report
Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock? [Yahoo! Finance]
6/20
08:39 am
allo
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse [Yahoo! Finance]
High
Report
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse [Yahoo! Finance]
6/20
08:30 am
allo
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
High
Report
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
6/12
12:39 pm
allo
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Medium
Report
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
5/31
08:03 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $11.00 price target on the stock.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $11.00 price target on the stock.
5/23
08:40 am
allo
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit [Yahoo! Finance]
5/23
08:30 am
allo
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Medium
Report
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
5/21
08:03 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $13.00. They now have an "outperform" rating on the stock.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $13.00. They now have an "outperform" rating on the stock.
5/16
08:14 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.
5/15
03:20 pm
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.
5/14
03:01 pm
allo
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag [Yahoo! Finance]
Low
Report
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag [Yahoo! Finance]
5/14
08:07 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target raised by analysts at Stifel Nicolaus from $4.40 to $4.60. They now have a "hold" rating on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target raised by analysts at Stifel Nicolaus from $4.40 to $4.60. They now have a "hold" rating on the stock.
5/13
04:47 pm
allo
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Low
Report
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
5/13
04:11 pm
allo
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]
Low
Report
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]
5/13
04:01 pm
allo
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Low
Report
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
5/6
08:30 am
allo
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Medium
Report
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update